Regional WHO HPV Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia; Murdoch Childrens Research Institute, Parkville, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia.
Regional WHO HPV Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia; Victorian Cytology Service, Carlton, Victoria, Australia; National Centre for Immunisation Research and Surveillance, University of Sydney, Westmead, NSW, Australia.
J Clin Virol. 2014 Jul;60(3):250-6. doi: 10.1016/j.jcv.2014.04.013. Epub 2014 May 5.
Data on the prevalence of cervical HPV genotypes in Australia by age and by grade of cytological abnormality are sparse.
Measure prevalence of HPV genotypes among 2620 Australian women by age and cytology status.
Women presenting for routine Pap smear screening were recruited from diverse regions, including a significant sample of Indigenous women. DNA extracts prepared from Thinprep specimens were HPV genotyped by Roche LINEAR ARRAY HPV.
HPV prevalence and genotype distribution were stratified by age (mean 32.6y) and Pap smear result (cytology normal in 86.7%). Overall HPV prevalence was 38.7% with high-risk HPV prevalence of 26.5%. Prevalence of HPV (66.3% in women<21y to 15.3% in women>40y), multiple HPV infection (45.5% in <21y to 5.8% in >40y) and vaccine-targeted genotypes (HPV 6/11/16/18) (34.1% in <21y to 2.4% in >40y) declined significantly with age. The six most common genotypes were: HPV 16 (8.3%), 51 (5.1%), 53 (4.7%), 62 (4.3%), 89 (3.9%) and 52 (3.8%). HR-HPV prevalence increased from 21.1% in women with normal cytology to 80.9% in those with cytologically predicted high-grade abnormalities (HGAs) (p<0.001). The most common genotypes in women with HGAs were HPV 16 (51.1%), 18 (14.9%), 52 (12.8%), 31 (10.6%), and 33 (10.6%): all HR-types.
Pre-vaccination cross-sectional prevalence of HR-HPV infection was high in this sample of Australian women attending for screening. HPV 16 was the commonest high-risk type detected at all ages and cytological grades.
澳大利亚按年龄和细胞学异常分级的宫颈 HPV 基因型流行率数据较为匮乏。
测量 2620 名澳大利亚女性中 HPV 基因型的流行率，按年龄和细胞学状态分层。
从不同地区招募了进行常规巴氏涂片筛查的女性，其中包括大量的土著女性。从 Thinprep 标本中提取的 DNA 采用罗氏线性阵列 HPV 进行 HPV 基因分型。
按年龄（平均 32.6 岁）和巴氏涂片结果（细胞学正常 86.7%）对 HPV 流行率和基因型分布进行分层。HPV 总流行率为 38.7%，高危型 HPV 流行率为 26.5%。HPV 流行率（21 岁以下妇女为 66.3%，40 岁以上妇女为 15.3%）、多重 HPV 感染（21 岁以下妇女为 45.5%，40 岁以上妇女为 5.8%）和疫苗靶向基因型（HPV 6/11/16/18）（21 岁以下妇女为 34.1%，40 岁以上妇女为 2.4%）随年龄显著下降。最常见的 6 种基因型为：HPV 16（8.3%）、51（5.1%）、53（4.7%）、62（4.3%）、89（3.9%）和 52（3.8%）。HR-HPV 流行率从细胞学正常的妇女的 21.1%增加到细胞学预测的高级别异常（HGAs）的妇女的 80.9%（p<0.001）。HGAs 妇女中最常见的基因型为 HPV 16（51.1%）、18（14.9%）、52（12.8%）、31（10.6%）和 33（10.6%）：均为 HR 型。
在接受筛查的澳大利亚女性样本中，HR-HPV 感染的疫苗接种前横断面流行率较高。HPV 16 是所有年龄和细胞学分级中最常见的高危型。
